Clinical Study Protocol for Targeting BCMA Autochimeric Antigen Receptor T Cell Infusion One-arm, Single-center, Open-label Clinical Trial of BCMA Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With BCMA-positive Relapsed/Refractory Multiple Myeloma
Latest Information Update: 02 Dec 2021
Price :
$35 *
At a glance
- Drugs Anti BCMA CAR T cell therapy PersonGen BioTherapeutics (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors PersonGen Biomedicine
- 10 Dec 2019 New trial record